146 related articles for article (PubMed ID: 16020974)
41. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Brandi M; Vici P; Lopez M; Valerio MR; Giotta F; Gebbia N; Schittulli F; Colucci G;
Semin Oncol; 2004 Apr; 31(2 Suppl 5):13-9. PubMed ID: 15199527
[TBL] [Abstract][Full Text] [Related]
42. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
[TBL] [Abstract][Full Text] [Related]
43. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M
Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859
[TBL] [Abstract][Full Text] [Related]
46. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
47. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
48. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Albertsson M; Johansson B; Friesland S; Kadar L; Letocha H; Frykholm G; Wagenius G
Med Oncol; 2007; 24(4):407-12. PubMed ID: 17917090
[TBL] [Abstract][Full Text] [Related]
49. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
50. Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.
Shao B; Song G; Li H; Dil L; Jiang H; Liang X; Yan Y; Zhang R; Ran R; Wang J; Liu X; You M
J BUON; 2018; 23(6):1583-1590. PubMed ID: 30610781
[TBL] [Abstract][Full Text] [Related]
51. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
[TBL] [Abstract][Full Text] [Related]
52. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
53. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Zhou NN; Teng XY; Jiang WQ; Liu DG
Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
[TBL] [Abstract][Full Text] [Related]
54. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Spiridonidis CH; Laufman LR; Carman L; Moore T; Blair S; Jones J; George C; Patel T; Roach R; Rupert R; Zangmeister J; Colborn D; Kuebler JP
Ann Oncol; 2001 Jan; 12(1):89-94. PubMed ID: 11249055
[TBL] [Abstract][Full Text] [Related]
55. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
[TBL] [Abstract][Full Text] [Related]
56. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Georgoulias VA
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
58. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
[TBL] [Abstract][Full Text] [Related]
59. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
